TRIMEDYNE STOCK HEATS UP WITH SIDE-FIRING LASER CLEARANCE FOR BPH, GAINS 156% IN MARCH; O-T-C INDEX SLIDES 2.6% FOR SECOND STRAIGHT MONTHLY DECLINE
This article was originally published in The Gray Sheet
Executive Summary
Trimedyne's receipt of 510(k) clearance for use of its side-firing laser to treat benign prostatic hyperplasia warmed up investor interest in the company in March, sending its stock ahead 156%, from 3-1/8 to 8. News of the clearance, the first for a laser to treat BPH, rekindled enthusiasm about sales and earnings prospects at the Irvine, California-based firm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.